Conditions: Blood Cancer Advanced B Cell Malignancies
Keywords: Phase I advanced B cell malignancies dose escalation CD19 Japanese
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: MEDI-551
Intervention descriptions: intervention 1: MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle

Protocol document: